American Association for Cancer Research

Program

* - Short talk from selected proffered abstracts

SUNDAY, SEPTEMBER 12

Opening Plenary Session

4:30 p.m.-6:00 p.m.

Welcome
Patricia S. Steeg, National Cancer Institute, Bethesda, MD, and Bruce R. Zetter, Children's Hospital Boston, Harvard Medical School, Boston, MA

Special Presentation
Healthcare reform: Implications for cancer research

Hon. S. Ward Casscells, University of Texas Health Science Center, Houston, TX

Keynote Address
New insights into tumor cell drug resistance
Joan S. Brugge, Harvard Medical School, Boston, MA

Plenary Session 1: The Influence of the Niche

Chairperson: David C. Lyden, Cornell University Weill Medical College, New York, NY
6:00 p.m.-8:30 p.m.

ALK: An exploitable new target in non-small cell lung cancer
Mace L. Rothenberg, Pfizer, Inc., San Diego, CA

The pre-metastatic niche: Adapting the foreign soil
David C. Lyden

Seed and soil hypothesis revisited
Rakesh K. Jain, Massachusetts General Hospital, Boston, MA

Hypoxia-induced genes that promote metastasis: New targets for therapy
Amato J. Giaccia, Stanford University School of Medicine, Stanford, CA

* Slow cycling self renewing JARID1B-positive cells are essential for long-term maintenance of malignant melanoma
Meenhard Herlyn, Wistar Institute, Philadelphia, PA

Opening Reception

8:30 p.m.-10:00 p.m.

 

MONDAY, SEPTEMBER 13

Continental Breakfast

6:30 a.m.-8:30 a.m.

Meet-the-Expert Sessions 1-2

7:00 a.m.-7:45 a.m.

Funding paradigms in the tumor microenvironment
Dinah S. Singer, National Cancer Institute, Rockville, MD

Hypoxic tumor microenvironment: Validation of novel metabolic targets
Jacques Pouysségur, Institute of Signaling, Developmental Biology, and Cancer Research, Nice, France

Plenary Session 2: Translational Targets I

Chairperson: George W. Sledge, Indiana University Cancer Center, Indianapolis, IN
7:45 a.m.-10:15 a.m.

Is the micrometastatic cell a clinical target?
George W. Sledge

Targeting TGF-beta to suppress metastasis
Lalage M. Wakefield, National Cancer Institute, Bethesda, MD

The role of tumor endothelin-1 in metastatic colonization of the lung
Dan Theodorescu, University of Colorado Comprehensive Cancer Center, Aurora, CO

Bone metastasis of lung cancer and its molecular-targeted therapy in the organ microenvironment
Saburo Sone, University of Tokushima Graduate School, Tokushima, Japan

* 14-3-3ζ cooperates with ErbB2 to promote ductal carcinoma in situ progression to invasive breast cancer by inducing epithelial-mesenchymal transition
Dihua Yu, University of Texas MD Anderson Cancer Center, Houston, TX

* Chemotherapy promotes lung metastasis formation in mouse models via a VEGFR-1-dependent mechanism
Laura G.M. Daenen, University Medical Centre, Utrecht, The Netherlands

Break

10:15 a.m.-10:45 a.m.

Concurrent Sessions 1-2

10:45 a.m.-12:15 p.m.

  • TME: Stroma

    Chairperson: Zena Werb, University of California, San Francisco, CA

    Targeting stromal proteases as therapy for cancer
    Samuel R. Denmeade, Johns Hopkins Kimmel Comprehensive Cancer Center, Baltimore, MD

    Adult stromal cells for the targeted therapy of gastrointestinal cancers
    Pierre Cordelier, Institut Louis Bugnard, Toulouse, France

    Role of the tumor microenvironment in breast cancer progression and response to therapy
    Zena Werb

  • MRS: Genomics of Primary Tumors and Metastases

    Chairperson: G. Steven Bova, Johns Hopkins University School of Medicine, Boston, MA

    Exploring clonality in lethal metastatic prostate cancer: Potential value in reducing complexity
    G. Steven Bova

    Comparing genomics of primary tumors and metastases for targets identification and biomarkers development in lung cancer
    Ignacio I. Wistuba, University of Texas MD Anderson Cancer Center, Houston, TX

    Epigenetic and microenvironmental regulation of metastatic dispersal in childhood malignancy
    Stefan Burdach, Technische Universität München, Munich, Germany

Lunch on own

12:15 p.m.-1:15 p.m.

Controversy Session: Anti-angiogenesis: Hot or Not?

1:15 p.m.-2:30 p.m.

The biology behind the successes and failures of VEGF-targeted therapies
Lee M. Ellis, University of Texas MD Anderson Cancer Center, Houston, TX

Preclinical modeling of adjuvant and metastatic antiangiogenic (and other drug) therapies
Robert S. Kerbel, University of Toronto Sunnybrook Health Sciences Centre, Toronto, ON, Canada

Plenary Session 3: Novel Molecular Pathways

Chairperson: Joan Massagué, Memorial Sloan-Kettering Cancer Center, New York, NY
2:30 p.m.-4:30 p.m.

Correlative biomarkers for anti-angiogenic therapy
Jeffrey W. Clark, Massachusetts General Hospital Cancer Center, Boston, MA

Metastasis meets microenvironment: Survival signals from the soil
Joan Massagué

Necdin regulation by Nm23-H1 and EBNA3C: Insights from a virus
Erle S. Robertson, Abramson Cancer Center of University of Pennsylvania, Philadelphia, PA

*A novel population of Neuropilin-1-Expressing Mononuclear Cells (NEMs) contributes to tumor vessel stabilization and normalization
Alessandro Carrer, ICGEB, Trieste, Italy

* The KISS1 metastasis suppressor appears to reverse the ‘Warburg Effect’™ by increasing mitochondrial number
Kyle P. Feeley, University of Alabama, Birmingham, AL

Break

4:30 p.m.-4:55 p.m.

Concurrent Sessions 3-4

4:55 p.m.-6:30 p.m.

  • TME: Inflammation and Immunity

    Chairperson: Alberto Mantovani, Istituto Clinico Humanitas, University of Milan, Rozzano, Italy

    Chemokines in tumor progression and metastasis
    Alberto Mantovani

    Inflammation and cancer: Reprogramming the immune microenvironment as an anticancer therapeutic strategy
    Lisa M. Coussens, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA

    Stem cells, inflammation, and tumor immunity: From bedside to the bench
    Madhav V. Dhodapkar, Yale School of Medicine, New Haven, CT

    * Spatial and temporal regulation of CXCR3 chemokine production and CD8 T cell infiltration in the metastatic melanoma microenvironment
    David W. Mullins, University of Virginia, Charlottesville, VA

  • MRS: Metastatic Colonization

    Chairperson: Carrie W. Rinker-Schaeffer, University of Chicago, Chicago, IL

    Using metastasis suppressors to dissect cancer cell-microenvironmental interactions during metastatic colonization
    Carrie W. Rinker-Schaeffer

    Novel mediators of tumor-stroma crosstalk in breast cancer bone metastasis
    Yibin Kang, Princeton University, Princeton, NJ

    * A mutant of the metastasis susceptibility gene Brd4 promotes EMT, stem cell-like conversion and metastatic progression in a mouse mammary tumor model
    Jude Alsarraj, National Institutes of Health, National Cancer Institute, Bethesda, MD

    Can we screen for anti-metastatic agents?
    Bruce R. Zetter, Children's Hospital Boston, Harvard Medical School, Boston, MA

Poster Session A

6:30 p.m.-8:30 p.m.

  • Genomics of Primary Tumors and Metastases
  • Inflammation and Immunity
  • The Influence of the Niche
  • Metastasis and the Matrix
  • Novel Molecular Pathways
  • Site Specific Metastasis
  • Stem Cells
  • Stroma
  • Translational Targets

 

TUESDAY, SEPTEMBER 14

Continental Breakfast

6:30 a.m.-8:30 a.m.

Meet-the-Expert Sessions 3-4

7:00 a.m.-8:00 a.m.

Neuroendocrine regulation of metastasis: Targeting the tumor macroenvironment
Steve Cole, University of California, Los Angeles, CA

Metastasis assays in vivo and ‘metastasis assays’ in vitro: What do they mean?
Danny R. Welch, University of Alabama, Birmingham, AL

Plenary Session 4: Dormancy

Chairperson: Ann F. Chambers, London Regional Cancer Center, London, ON, Canada
8:00 a.m.-10:00 a.m.

Disseminated tumor cells in prostate cancer: Insights into bone metastases, epithelial to mesenchymal transition (EMT), and tumor cell dormancy
Robert L. Vessella, University of Washington Medical Center, Seattle, WA

Imaging experimental models of tumor metastasis and dormancy
Ann F. Chambers

Stress signaling mechanisms and dormancy of disseminated tumor cells
Julio Aguirre-Ghiso, Mount Sinai School of Medicine, New York, NY

An LPA1 antagonist, Debio 0719, acts as a metastasis suppressor in breast cancer
Jean-Claude A. Marshall, National Institutes of Health, Bethesda, MD

Break

10:00 a.m.-10:30 a.m.

Generation X Session: The Future of Tumor Progression

Chairperson: Yves A. DeClerck, USC/Children's Hospital Los Angeles, Los Angeles, CA
10:30 a.m.-12:00 p.m.

Introduction
Generation X: The 13th wave of scientists?
Yves A. Declerck

* A novel role of Notch signaling in breast cancer bone metastasis
Nilay Sethi, Princeton University, Princeton, NJ

* The role of stroma and STAT1 in radioresistance of breast cancer
Mirjam C. Boelens, Abramson Family Cancer Research Institute, University of Pennsylvania, Philadelphia, PA

* Membrane type 1-matrix metalloproteinase cooperates with K-rasG12D to generate pancreatic tumors with pronounced fibrosis
Hidayatullah G. Munshi, Northwestern University, Chicago, IL

* Recombinant human erythropoietin (rHuEPO) in combination with chemotherapy increases breast cancer metastasis in pre-clinical mouse models Benjamin Hedley, London Health Sciences Centre, London, ON, Canada

 

Lunch on own

12:00 p.m.-1:30 p.m.

Metastasis Research Society Meeting

Open to MRS members only
12:00 p.m.-1:30 p.m.

Concurrent Sessions 5-6

1:30 p.m.-3:30 p.m.

  • Metastasis and the Matrix

    Chairperson: Valerie M. Weaver, University of California, San Francisco, CA

    The force journey of a tumor cell
    Valerie M. Weaver

    Microenvironments of carcinoma cell dissemination and metastasis: Insights derived in vivo
    John S. Condeelis, Albert Einstein College of Medicine, Bronx, NY

    Title to be announced
    Linda G. Griffith, Massachusetts Institute of Technology, Cambridge, MA

    * Role of versican in bladder cancer metastasis to the lungs
    Neveen Said, University of Virginia, Charlottesville, VA

    *Microtentacles arising from imbalanced cytoskeletal forces promote the reattachment of circulating breast tumor cells in lung capillaries
    Stuart S. Martin, University of Maryland School of Medicine, Baltimore, MD

  • MRS: Site Specific Metastasis

    Chairperson: Andrea M. Mastro, Penn State University, University Park, PA

    An in vitro model of the vicious cycle of cancer metastasis in the bone
    Andrea M. Mastro

    Translational leads for the treatment of breast cancer brain metastasis
    Diane Palmieri, National Cancer Institute, Bethesda, MD

    The tumor microenvironment at different stages of the hepatic metastasis process
    Fernando Vidal-Vanaclocha, CEU-San Pablo University School of Medicine and Madrid Hospital Foundation, Madrid, Spain

    * Syndecans in breast cancer brain metastasis
    Jennifer E. Koblinski, Northwestern University, Chicago, IL

    * Vascular co-option in brain metastasis
    Ruth Muschel, University of Oxford, Oxford, England

Break

3:30 p.m.-4:00 p.m.

Paget-Ewing Award Lecture

4:00 p.m.-5:00 p.m.

microRNA-mediated regulation of the tumor angiogenic switch
David A. Cheresh, University of California San Diego, Moores Cancer Center, La Jolla, CA

Poster Session B

5:30 p.m.-7:30 p.m.

  • Dormancy
  • Genomics of Primary Tumors and Metastases
  • Metastasis and the Matrix
  • Metastatic Colonization
  • Novel Molecular Pathways
  • Site Specific Metastasis
  • Stroma
  • Translational Targets
  • Other

Conference Banquet

7:30 p.m.-10:30 p.m.

Join us for dinner, networking, and music.

Please note that tickets for this event are $50 per person and may be purchased when registering for the conference. Guests are welcome to attend, but they must purchase a ticket.

 

WEDNESDAY, SEPTEMBER 15

Continental Breakfast

6:30 a.m.-8:30 a.m.

Meet-the-Expert Sessions 5-6

7:00 a.m.-7:45 a.m.

Cancer micrometastasis and circulating tumor cells
Klaus Pantel, University Medical Center, Hamburg, Germany

Natural products lead discovery in the molecular targets laboratory
James B. McMahon, National Cancer Institute, Frederick, MD

Plenary Session 5: Stem Cells

Chairperson: Max S. Wicha, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI
7:45 a.m.-10:00 a.m.

Regulation of breast cancer stem cells by the tumor microenvironment
Max S. Wicha

The role of developmental molecules and miRs in the induction of cancer stem cells and metastasis
Heide L. Ford, University of Colorado School of Medicine, Aurora, CO

Solid tumors target the hematopoietic stem cell niche during metastasis
Russell S. Taichman, University of Michigan, Ann Arbor, MI

* Microenvironment enriched metastatic cancer stem cells mediate prostate cancer metastasis
Mahipal V. Suraneni, University of Texas MD Anderson Cancer Center, Smithville, TX

Break

10:00 a.m.-10:30 a.m.

Plenary Session 6: Translational Targets II

Chairperson: Patricia S. Steeg, National Cancer Institute, Bethesda, MD
10:30 a.m.-12:00 p.m.

Signalling pathways as targets for therapy
Suzanne A. Eccles, Cancer Research UK Centre for Cancer Therapeutics, McElwain Laboratories, Sutton, Surrey, United Kingdom

The role of adipocytes in promoting metastasis
Ernst R. Lengyel, University of Chicago, Chicago, IL

Functional role of RANKL in metastasis and tumorigenesis: Skeletal and extraskeletal effects
William C. Dougall, Amgen, Inc., Seattle, WA

Departure